Abstract
Clinical evidence suggests that, compared with alendronate, risedronate reduces fracture risk faster and more potently, with less bone mass gain. We tested the hypothesis that risedronate improves bone quality faster than alendronate using calcium-deficient, ovariectomized (OVX) rats. Female Sprague–Dawley rats at 24 weeks of age were divided into sham-operated and OVX groups and fed a low-calcium (0.05 %) diet under paired feeding. After 12 weeks, OVX rats were divided into five groups and treated with vehicle, risedronate (3.5 and 17.5 μg/kg/week, s.c.) or alendronate (7 and 35 μg/kg/week, s.c.). Rats were killed 6–8 weeks later and the bone architecture and strength of the left femur were evaluated by micro-computed tomography and a three-point bending test. Trabecular bone mineral density (BMD), number and thickness were significantly lower in OVX rats than in the sham-operated group. Cortical BMD, bone area (Ct.Ar), and thickness (Ct.Th) were similarly decreased. Risedronate significantly improved Ct.Ar (+8 %) and Ct.Th (+9 %) at 6 weeks, while alendronate only caused a significant improvement in Ct.Ar (+8 % at 6 weeks) and only at the higher dose. At 8 weeks, both risedronate and alendronate significantly increased trabecular BMD compared with the vehicle. Bone strength parameters showed a significant correlation between Ct.Ar and Ct.Th. Risedronate significantly improved maximum load at 6 weeks, while alendronate failed to produce any significant changes. Our results suggest that risedronate is superior to alendronate at improving cortical bone architecture and strength, and that enhanced bone quality partly accounts for risedronate’s efficacy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
National Institutes of Health (2000) Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 17:1–45
Patsch JM, Burghardt AJ, Yap SP, Baum T, Schwartz AV, Joseph GB, Link TM (2013) Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res 28:313–324
Tsugeno H, Fujita T, Goto B, Sugishita T, Hosaki Y, Ashida K, Mitsunobu F, Tanizaki Y, Shiratori Y (2002) Vertebral fracture and cortical bone changes in corticosteroid-induced osteoporosis. Osteoporos Int 13:650–656
Rogers MJ, Crockett JC, Coxon FP, Monkkonen J (2011) Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49:34–41
Russell RGG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759
Russell RGG (2011) Bisphosphonates: the first 40 years. Bone 49:2–19
Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME (2008) A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International. Int J Clin Pract 62:575–584
Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R (2007) Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 18:25–34
Bullamore JR, Gallagher JC, Wilkinson R, Nordin BEC (1970) Effect of age on calcium absorption. Lancet 2:535–537
Hodgkinson A, Aaron JE, Horsman A, McLachlan MS, Nrodin BE (1978) Effect of oophorectomy and calcium deprivation on bone mass in the rat. Clin Sci Mol Med 54:439–446
Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25:1468–1486
Turner CH, Burr DB (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14:595–608
Zhang Y, Lai Wan-Ping, Wu Chun-Fu, Favus MJ, Leung Ping-Chung, Wong Man-Sau (2007) Ovariectomy worsens secondary hyperparathyroidism in mature rats during low-Ca diet. Am J Physiol Endocrinol Metab 292:E723–E731
Kaastad TS, Reikeras O, Madsedn JE, Stromme JH, Obrant KJ, Nordsletten L (1997) Effect of clodronate on cortical and trabecular bone in ovariectomized rats on a low calcium diet. Calcif Tissue Int 61:158–164
Roelfs AJ, Stewart CA, Sun S, Blazewska KM, Kashemirov BA, McKenna CE, Russell RGG, Rogers MJ, Lundy MW, Ebetino FH, Coxon FP (2012) Influence of bone affinity on the skeletal distribution of fluorescently labeled bisphosphonates in vitro. J Bone Miner Res 27:835–847
Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone mineral density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289
Imai K (2011) Vertebral fracture risk and alendronate effects on osteoporosis assessed by a computed tomography-based nonlinear finite element method. J Bone Miner Metab 29:645–651
Conflict of Interest
Tetsuo Yano, Mei Yamada, Tomoyuki Konda, and Makoto Shiozaki are an employee of Ajinomoto Pharmaceuticals Co., Ltd. Daisuke Inoue serves as a consultant for Ajinomoto Pharmaceuticals Co., Ltd.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yano, T., Yamada, M., Konda, T. et al. Risedronate improves bone architecture and strength faster than alendronate in ovariectomized rats on a low-calcium diet. J Bone Miner Metab 32, 653–659 (2014). https://doi.org/10.1007/s00774-013-0543-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-013-0543-9